chronic iron overload
Haematology · 2006–2020
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| deferasirox Chronic iron overload due to disorders of haemopoiesis, including transfusion-dependent malignant and non-malignant disorders of erythropoiesis, and… | Nov 2020 | Recommended | none received |
| deferasirox Treatment of chronic iron overload due to disorders of haemopoiesis, including transfusion-dependent anaemias, non-transfusion-dependent thalassaemia, and… | Jul 2018 | Recommended | 6 individuals |
| deferasirox Treatment of chronic iron overload associated with transfusion-dependent malignant disorders of erythropoiesis and non-transfusion-dependent thalassaemia. | Jul 2015 | Not recommended | 3 individuals Thalassaemia Society of NSW · Leukaemia Foundation |
| deferasirox Chronic iron overload in patients with non-malignant disorders of erythropoiesis who are transfusion-dependent. | Nov 2014 | Recommended with restriction | no section in document |
| deferasirox Chronic iron overload associated with the treatment of disorders of erythropoiesis in adults, adolescents and children 6 years and older, and in paediatric… | Jul 2006 | Recommended with restriction | no section in document |
| deferasirox Chronic iron overload associated with the treatment of disorders of erythropoiesis in adults, adolescents and children 6 years and older, and in paediatric… | Jul 2006 | Recommended with restriction | no section in document |
Who spoke
Thalassaemia Society of NSW · Leukaemia Foundation
What the PBS pays
$4M in government benefit over 2024–25, across 6,806 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| deferasirox | $4M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| desferrioxamineDBL DESFERRIOXAMINE MESYLATE FOR INJECTION 500mg powder for injection | 1996 | 4 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.